Although T cell depletion of allografts used in BMT has reduced GVHD, it has been associated with inferior engraftment and an increased risk of relapse. We have found that T cell depletion by counterflow centrifugal elutriation (CCE) also results in depletion of CD34 
of donor marrow engraftment and T lymphocyte-mediated processes such as GVL effect and GVHD. 2 Unmanipulated marrow from related donors engrafts efficiently and has the theoretical advantage of improved survival due to GVL effect but at the expense of high rates of morbidity and mortality related to acute and chronic GVHD. 3 To reduce GVHD-related mortality different methods of T cell depletion have been used since the mid-1980s [4] [5] [6] but have not had a significant impact on overall survival due to the offsetting effects of increased graft failure and relapse. 7, 8 We and others have reported results of phase I/II clinical trials which used counterflow centrifugal elutriation (CCE) to lymphocyte-deplete allogeneic BM prior to transplantation. [9] [10] [11] [12] This method separates bone marrow cells on the basis of sedimentation properties and yields nearly complete recovery of cells in several size fractions. 4 In our studies, grafts consisted of the large cell fraction which was depleted of lymphocytes by 2-3 logs and which contained most of the CFU-GM in the BM harvest. Patients also received cyclosporin A (CsA) for 180 days as immunoprophylaxis of GVHD. However, problems were encountered that could be explained either by inhibition of engraftment by host T cells (a host-versus-graft effect) or by a deficiency of donor stem cells. Graft failure up to 10% was seen. 11 Engraftment kinetics appeared to vary with the lymphocyte composition of the graft. At a lower dose of lymphocytes (5 × 10 5 vs 1 × 10 6 lymphocytes/kg ideal body weight (IBW)) engraftment of granulocytes and platelets was prolonged. Median time to ANC Ͼ500/l was 21 days compared to 18 days, respectively; median time to an unsupported platelet count of 50 000/l was 41 days compared to 29 days, respectively. Also, stable mixed hematopoietic chimerism as determined by RFLP analysis of bone marrow aspirates was seen in 10% of patients receiving the lower lymphocyte dose. On the other hand, there was a significant reduction in the incidence of overall acute GVHD at the lower lymphocyte dose (22% compared to 45% at the higher dose). Clinically significant acute GVHD was seen only at the higher lymphocyte dose at an incidence of 13%. 9, 10 Subsequently, it was shown in the murine model by Jones et al 13 that the long-term marrow repopulating cell was enriched in the small cell elutriation fractions, whereas the committed hematopoietic progenitors predominated in the lymphocyte-depleted large cell fraction providing a cellular basis for the two phases of engraftment seen on serial BMT in mice.
14 Furthermore, flow cytometric analysis of clinical CCE products demonstrated that about half of human CD34
+ cells were found in the small cell elutriation fractions. 15 These fractions are lymphocyte-rich and were excluded from the allografts in our prior studies. It seemed likely, therefore, that poorer engraftment compared to unmanipulated marrow grafts could have resulted from depletion of hematopoietic stem cell precursors in the manipulated allograft. Preliminary studies showed that the majority of small CD34 + cells could be recovered in high purity and yield by positive immunoselection. 15, 16 We now report the results of a phase II clinical trial of CD34 + cell augmentation of elutriated allografts and GVHD prophylaxis in patients undergoing BMT for high-risk hematologic malignancies that demonstrates: (1) improved hematopoietic engraftment comparable to that of unmanipulated allografts; (2) low rates of graft failure, mixed chimerism, GVHD and transplant-related mortality (TRM); and (3) EFS for selected subsets of patients that is comparable to unmanipulated allografts.
Patients and methods

Patient eligibility
Patients enrolled were those with: (1) acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in complete remission (CR1, CR2, CR3) or relapse; (2) Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) in CR, partial remission (PR) or relapse with resistant disease; (3) myelodysplastic syndrome (MDS) or AML secondary to MDS; (4) chemo-sensitive or stable multiple myeloma (MM); or (5) chronic lymphocytic leukemia (CLL). Patients with AML in CR1 had to have at least one poor risk factor including white blood cell count Ͼ20 000, CD34 + blasts, unbalanced translocations or FAB classifications M6 or M7.
Informed consent
The protocols for marrow fractionation by CCE, selection of CD34 + cells and intensive myeloablative therapy before transplantation were reviewed and approved by the Joint Committee on Clinical Investigation of The Johns Hopkins Medical Institutions. Informed consent was obtained from all patients.
Transplantation procedure
All sibling marrow donors were genotypically HLA-A, B, C and DR identical (6/6) with the recipients as determined by serologic HLA class I and molecular HLA class II typings. Marrow harvest and pre-transplant preparative regimens were described previously. 10 The mean number of mononuclear cells/kg IBW harvested was 5.1 Ϯ 0.2 × 10 
CCE and CD34
+ cell selection A detailed description of the separation methodology used in this study has been published. 17 Briefly, bone marrow buffy coat cells were prepared on a COBE Spectra apheresis system set for bone marrow processing (COBE BCT, Lakewood, CO, USA) and loaded into a Beckman JE-10X (Beckman Instruments, Palo Alto, CA, USA) elutriation rotor and chamber at a total flow rate of 50 ml/min, rotor speed 3000 r.p.m. and temperature of 20°C. The buffy coat that was loaded into the elutriation system contained 25 Ϯ 1.0% of harvested mononuclear cells. CCE was performed as described previously. 9, 10 The elutriation load, 110 ml/min, 140 ml/min and R/O fractions contained 8.6 Ϯ 1.8%, 46.7 Ϯ 2.1%, 14.1 Ϯ 1.1% and 31.3 Ϯ 1.5% of the applied cells, respectively. The lymphocyte-depleted R/O fraction was issued to the BMT unit immediately and infused without additional filtration.
After elutriation, the load, 110 ml/min and 140 ml/min fractions were pooled and concentrated on a COBE 2991 cell processer and washed with 1 l of RPMI medium. Cells were resuspended in RPMI medium containing 0.1% human serum albumin (HSA) at a concentration of 2 × 10 10 cells/mg of biotinylated monoclonal antibody 12.8 to CD34 antigen (CellPro, Bothell, WA, USA) and incubated at room temperature for 25 min. Cells then were concentrated in a COBE 2991 and washed with 1 l of phosphate-buffered saline (PBS) and resuspended in 300 ml of PBS containing 0.1% HSA. The cell suspension was applied to an automated Ceprate SC Stem Cell Concentrator (provided by CellPro) which consisted of avidin-coated beads. CD34 + cells were then eluted from the column in the same buffer by gentle agitation and infused directly. Compared to unmanipulated BM which contained 0.8 Ϯ 0.6% CD34 + cells, the buffy coat contained 3.4 Ϯ 0.2% CD34 + cells, the elutriation R/O fraction contained 4.9 Ϯ 0.5% CD34 + cells and the pooled load, 110 ml/min and 140 ml/min fractions contained 3.4 Ϯ 0.3% CD34 + cells. Purity of the CD34 + cell fraction eluted from the Ceprate column was 78.7 Ϯ 1.5%; the yield of CD34 + cells off the column was 61.3 Ϯ 6.1%.
The elutriation device and the CellPro Ceprate SC Stem Cell Concentrator were approved for use under FDA BB IDE 4683 with the proviso that the allograft consist of CD34 + cells selected from the small cell elutriation fractions and of the R/O fraction.
Supportive care
Peri-transplant supportive care of patients has been described previously. 9, 10 Platelet transfusions were given when the platelet count fell below 20 × 10 9 /l and packed red cells were given to maintain a hematocrit above 25%.
CsA immunosuppressive therapy
All patients received CsA beginning on day −2 at an i.v. dose of 5 mg/kg IBW. CsA dose was decreased to 2.5 mg/kg i.v. on days 3-14 post-BMT. Patients were then converted to CsA 10 mg/kg p.o. as tolerated on day 15. For patients receiving Ͼ30 days of CsA the oral dose was decreased to 7.5 mg/kg p.o. on day 51. Oral CsA was tapered over a 7-day period prior to discontinuation of the drug at either 30 days, 80 days or 180 days as described in the text.
Flow cytometry
Phycoerythrin-conjugated monoclonal antibodies to CD34 (HPCA-2) and to CD3 and fluorescein isothiocyanate-conjugated monoclonal antibody to CD45 were obtained from Becton Dickinson (San Jose, CA, USA). Antibody labeling of cells and flow cytometric analysis has been described previously.
18,19
Colony assays
Granulocyte/monocyte colony-forming units (CFU-GM) were assayed using a methylcellulose culture system. 20 Colonies were scored on day 14.
Statistical methods
In the text, summary values are reported as mean Ϯ 95% confidence interval (CI). Event times were measured from the date of BMT. Date and stage of GVHD was determined by the GVHD team according to defined criteria.
3,10 EFS is defined as time until death or relapse; relapse-free survival (RFS) is defined as time until relapse. Event times were analyzed as of 3 January 1997. Event time distributions were estimated using the product limit method of Kaplan and Meier. 21 Confidence intervals for the median survival times were determined by the method of Brookmeyer and Crowley. 22 Heterogeneity was determined by log-rank test. The proportional hazards regression model of Cox 23 was used to compare event time distributions and to assess the effect of more than one prognostic factor. Contingency tables were analyzed by the 2 method. Analysis was performed using STATA or SAS statistical software.
Results
Clinical characteristics
Between May 1993 and July 1996, 110 consecutive patients with high-risk hematologic malignancies were enrolled in this study. Clinical characteristics are described in Table 1 . The male to female ratio was 1.2:1. Of the donor-recipient pairings, 21% were female-female, 23% were femalemale, 24% were male-female and 32% were male-male.
Bone marrow graft
Characterization of the buffy coat starting material and the CD34 + augmented, elutriated allografts are shown in Table 2 . CD34
+ cell-augmented, elutriated allografts contained approximately 10-fold fewer mononuclear cells but approximately the same absolute numbers of CD34 + cells 28 (26) and CFU-GM as unmanipulated grafts. On average, there was a 250-fold reduction of CD3 + T lymphocytes in the manipulated grafts.
Engraftment
Transplantation of CD34
+ -augmented marrow grafts resulted in median days to neutrophil (Ͼ500/l) and platelet (Ͼ50 000/l) engraftment of 16 days (95% CI: 15-18 days) and 25 days (95% CI: 22-31 days), respectively, as shown in Figure 1a and b. These results represent an improvement over the kinetics of neutrophil and platelet engraftment seen at this Center with elutriated marrow only (21 days and 41 days, respectively 10 ) and compare favorably with unmanipulated marrow at this center (17 days and 22 days, respectively 11, 15 ). When the analysis of engraftment kinetics was stratified by disease ( Figure 1c and d), heterogeneity in neutrophil engraftment was observed by log-rank test with significantly earlier engraftment in patients with MM (P = 0.004). There was no significant difference between the remaining curves for neutrophil engraftment or among the curves for platelet engraftment. A number of patients with ALL, AML, MDS and NHL showed late engraftment of platelets (Figure 1d) . No patients received gancyclovir prophylactically.
Multivariate analysis was performed to test association of granulocyte and platelet recovery with several covariates including the number of cells per graft (total, CFU-GM or CD34 + ), gender and age. A significant association was found only between CFU-GM and neutrophil recovery (P = 0.03).
Graft failure
There were five graft failures in 110 patients for an overall incidence of 4.5%. Four of these patients were classified 950 as failure to engraft with grade 4 marrow/blood toxicity persisting for up to 59 days post-BMT. Two of these patients with AML in CR2 or CR3 had received transfusions of donor platelets prior to BMT and were alloimmunized. Another patient had secondary AML with a 5 year history of transfusion-dependent MDS and also was alloimmunized at the time of BMT. The fourth patient had a history of aplastic anemia for 3 years which evolved into MDS. Three of these patients received salvage BMT with an unmanipulated graft (the condition of the fourth did not permit further preparative therapy for transplant). Only one patient is still surviving at 210 days with relapsed MDS and remains platelet-dependent. In contrast, the patient with late graft failure at Ͼ155 days post-BMT was a 24-yearold man with AML in CR1 who engrafted appropriately post-salvage BMT but who died at 424 days of severe GVHD of the skin, gut and liver which developed atypically at 8-9 months following his boost with unmanipulated marrow. There was no evidence for a suboptimal graft in any of these patients. The total number of mononuclear cells, CD34 + cells and CFU-GM per graft were all within the 95% confidence intervals for these graft parameters.
GVHD
Similar to previous clinical trials using standard elutriation, 9 ,10 the incidence of GVHD remains low with CD34 + -augmented, elutriated marrow grafts (Table 3) . Standard elutriation requires post-BMT CsA prophylaxis both to prevent GVHD and to ensure engraftment. 24 In earlier studies, 3/4 patients who received an elutriated graft without CsA lost their grafts. 11, 24 It was unclear to what extent CD34 + cell dose and CsA prophylaxis affected engraftment or whether long-term CsA prophylaxis was an integral part of the low incidence of GVHD seen in recipients of elutriated grafts. We also wanted to shorten duration of CsA to reduce undesirable side-effects such as hypertension and renal insufficiency. Accordingly, after the trial had begun with 10 patients having received 180 days of CsA prophylaxis, the trial was amended to vary the duration of drug administration (30 days, 80 days or 180 days) sequentially. Table 3 shows that the overall incidence of acute GVHD was 28% but that the incidence of clinically significant, acute GVHD (Ͼstage 1) was only 11%. Furthermore, the incidence of clinically significant, acute GVHD was dependent on the duration of CsA immunosuppression. There was no difference in the incidence of acute GVHD (Ͼstage 1) between patients who received 80 days (n = 46) or 180 days (n = 28) of CsA (P = 0.606) so the results were pooled and compared to those of patients who received 30 days CsA (n = 29). There was significantly greater GVHD in the group receiving 30 days of CsA (23%) than in the group Table 3 Incidence of graft-versus-host disease receiving у80 days of CsA (5%, P = 0.006). Comparisons among CsA groups were performed as a post-hoc analysis.
The incidence of extensive, chronic GVHD approached but did not achieve statistical significance between the CsA groups. Overall incidence of chronic GVHD was 15%. There was a 23% incidence in the 30-day group compared to an 11% incidence in the у80-day group (P = 0.085). However, there was a significant difference between the groups in the number of patients with chronic GVHD who had prior acute GVHD (80% in the 30-day group vs 25% in the у80-day group, P = 0.019).
Mixed chimerism
Southern blot analysis of RFLP was used to evaluate hematopoietic chimerism in the 78 patients who survived beyond the peri-transplant period (Ͼ100 days post-BMT). 25 There was no evidence of persistent, mixed chimerism (Ͼ20% host BM cells). A shift to mixed chimerism from 100% donor engraftment was seen in 15 patients (19%) but in 14 relapses were documented and on this basis the remaining patient with mixed chimerism is at risk for relapse although this is not yet documented hematologically.
Mortality
Overall mortality for the study was 56/110 patients (51%) at a median follow-up of 611 days (range 162-1323 days). Mortality data were stratified with respect to deaths in the peri-transplant period (р100 days post-BMT) vs late-recovery period (Ͼ100 days post-BMT) and also as a function of GVHD prophylaxis, as shown in Table 4 . Seven patients who had received an indeterminate 30-80 days of CsA Number of patients at risk excludes two patients who received a second, unmanipulated BMT at greater than 100 days post-BMT. VOD = veno-occlusive disease; HUS = hemolytic uremic syndrome.
were excluded from this analysis. As expected, the causes of death differed markedly between the peri-transplant and late-recovery periods; in the peri-transplant period 75% of deaths was due to graft failure, acute GVHD, veno-occlusive disease, organ failure and hemorrhage while in the laterecovery period 72% of deaths was due to relapse-related causes. There was no significant difference in the incidence of death due to infections between the two time periods (4-6%, P = 0.475).
Overall TRM was 26%. There was a trend toward higher TRM in the group of patients receiving 30 days of CsA prophylaxis (P = 0.091), accounted for entirely by excess mortality in the peri-transplant period. TRM at Ͻ100 days post-BMT of patients р50 years of age (n = 89) was 12% compared to 43% for patients Ͼ50 years of age (n = 21, P = 0.001). There was no disease-specific effect on TRM which was distributed approximately equally among the various diagnoses.
Survival
Rates of relapse and survival were not primary endpoints in this phase II trial of engraftment and GVHD prophylaxis. Because of the number of different hematologic malignancies which were also heterogeneous with respect to chemo-sensitivity it was possible to estimate rates of relapse and survival only for limited, small subsets of patients. Furthermore, the median age of patients in this study (43 years of age) was significantly older than historical controls making direct comparison difficult. However, two small groups of patients are worth noting: (1) relapse rate and EFS at 3 years for patients with MDS or secondary AML (n = 19) was 38% and 52%, respectively; (2) relapse rate and EFS at 3 years for patients with multiple myeloma (n = 19) was 47% and 30%, respectively. Overall RFS and EFS at 3 years for the entire study were 50% and 35%, respectively.
Discussion
Previous studies of elutriated marrow allografts have been associated with delayed engraftment kinetics, a graft failure rate of up to 10% and demonstration of mixed hematopoietic chimerism.
9,10,12 Subsequently, it was realized that a large proportion of primitive, CD34
+ stem cells in the marrow harvest were discarded in the small cell elutriation fractions containing T lymphocytes. 13, 15 This study shows that elutriation of marrow combined with positive selection of CD34 + cells from the small cell fractions was tightly controlled and resulted in nearly complete recovery of putative stem cell populations and a 250-fold reduction in T cells. Within the limitations of a phase II trial, it appears that a two-fold augmentation of total CD34
+ cells in elutriated marrow allografts confers an advantage in both early and late phases of bone marrow engraftment. Early engraftment kinetics of neutrophils and platelets were similar to those of unmanipulated allografts. 11, 16, 26, 27 This result likely reflects the observed enrichment of CD34 + committed progenitor cells and is consistent with a multivariate analysis of engraftment parameters showing a significant association only between CFU-GM dose and neutrophil recovery as described previously. 20, 28 No significant dose-response was observed between total CD34
+ cell dose and neutrophil or platelet recovery in contrast to a recent report. 29 However, the lowest dose of total CD34
+ cells infused in our study was approximately 1 × 10 6 cells/kg, a number which may be greater than the necessary threshold to see an effect on early engraftment, also suggested by studies on peripheral blood stem cells. 30 Assessment of chimerism by RFLP analysis at various times up to 2 years post-BMT showed durable engraftment by donor stem cells. Exceptions were patients in whom mixed chimerism (Ͼ20% recipient) was predictive of relapse, a finding which differed from earlier studies of elutriated marrows in which the stem cell dose was lower, and stable mixed chimerism was observed frequently. 9, 10, 12 The rate of failure to engraft was 3.6% with CD34 + augmented allografts compared to the 5-10% reported previously for the standard method of bone marrow elutriation. [10] [11] [12] Of the four patients in this study who failed to engraft, two with AML had received platelet transfusions from their marrow donors pre-BMT suggesting that prior sensitization to donor histocompatibility antigens may have led to immune rejection of the grafts as described clinically 31, 32 and in pre-clinical models. 33 The other two early graft failures were in patients with MDS one of whom also had a history of aplastic anemia, a known risk factor for graft rejection. 31 The second patient with MDS (5q − syndrome) had an extensive history of platelet transfusions, another recognized risk factor for graft rejection. 31, 32 Late graft failure was observed in only one patient at 5 months post-BMT in the absence of documented infection, GVHD or relapse, and remains unexplained. Several large studies using various methods of T cell depletion showed that the rate of failure to engraft ranged from 3 to 9% and that late graft failures increased the overall incidence of graft failure to 10-15%. 6, 12, 34, 35 Clearly, graft failure remains a problem with T cell-depleted allografts compared to the negligible frequency (approximately 0.1%) observed for unmanipulated marrow allografts. 36 However, this frequency was minimized in the current study and all but one of the graft failures were explainable by known risk factors.
Recently, it was shown that allografts with the same CD34
+ cell content and relative T cell depletion as described in this report could be derived by applying CD34 + immunoselection methodology directly on bone marrow buffy coat preparations or peripheral blood leukopheresis products. [37] [38] [39] [40] Cornetta et al 37 reported a pilot study in which patients received CD34
+ selected bone marrow cells followed by steroids tapered over 6 weeks. In the presence of exogenous growth factor, neutrophil engraftment was rapid but a higher rate of clinically significant GVHD (29%) was observed compared to our study (5%) reflecting, perhaps, either the method of graft manipulation or limited GVHD prophylaxis post-BMT. The incidence of chronic GVHD was not reported. In another small study, Link et al 38 compared allografts composed of CD34 + selected bone marrow and CD34 + selected, mobilized peripheral blood to allografts of unselected bone marrow and CD34 + selected, mobilized peripheral blood. No difference in the rate of engraftment was observed between the two groups both of which were more rapid than historical controls of unselected bone marrow. The incidence of acute GVHD was also high in this study (20-40%) and there were no data reported on chronic GVHD.
A randomized trial will be necessary to address the question of whether CD34 + selection of bone marrow buffy coat cells is sufficient for T cell depletion without the added complexity of elutriation and still result in a comparable clinical outcome. Recently, we presented a theoretical consideration of this question with respect to cell separation. 16 Lymphocyte composition of the allograft obtained by direct CD34
+ selection of the buffy coat would differ, however, from that of this study which was enriched for large T lymphocytes (large:small = 4:1 compared to an estimated 1:40 ratio for CD34 + selected bone marrow). It is unclear if such a difference would affect the incidence of GVHD. Phenotypic and functional analyses of large and small T lymphocyte fractions derived by elutriation are currently in progress to determine if there are qualitative differences between these lymphocyte subpopulations. We do know that allografts obtained from peripheral blood leukopheresis products by direct CD34
+ selection containing total numbers of T lymphocytes comparable to this study resulted in a incidence of both acute and chronic GVHD that was greater than 80%. 41 Whether this result reflects qualitative differences between bone marrow and peripheral blood sources of stem cells or differences in T cell depletion methodology awaits further investigation.
The current method of CD34 + cell-augmented, elutriated allografts combined with CsA immunoprophylaxis for у80 days post-BMT and standard supportive care has resulted in some of the lowest rates of clinically significant acute GVHD (5%) seen in a large cohort of allogeneic BMT patients. Although not directly comparable because of lower median age (Ͻ30 years) and variable CsA immunoprophylaxis, two large registry studies of T cell-depleted marrows reported a 15-21% incidence of acute GVHD (Ͼstage 1). 2, 6 By contrast, the incidence of acute GVHD (Ͼstage 1) reported for unmanipulated, allogeneic transplants is about 40%. 2, 42 The incidence of extensive, chronic GVHD (11%) observed in this study was comparable to that reported previously for T cell-depleted allografts by the IBMTR. 2 The incidence of extensive, chronic GVHD in unmanipulated allografts is about 20% 2 and is associated with considerable morbidity and mortality. 3 Duration of immunoprophylaxis with CsA had a significant effect on the incidence of acute and chronic GVHD. Increasing prophylaxis from 30 days to у80 days resulted in an almost five-fold decrease in acute GVHD and a two-fold decrease in chronic GVHD. There was no association between CsA dosing and graft failure in this series.
An uncommon finding in allogeneic bone marrow transplantation is the development of post-transplant lymphoproliferative disease (PTLD). 43, 44 In this study, a single patient developed PTLD (Ͻ1%). Analysis of Epstein-Barr virus infection and details of treatment of his PTLD are presented elsewhere (I Flinn et al, submitted for publication).
TRM is known to be age-dependent. 45 Thus, the overall TRM of 26% observed in this study is low for a high-risk patient population with a median age of 43 years and compares favorably to that of a number of previous large studies of T cell-depleted allografts where the median age was about 30 years. 6, 12, 35, 46 By contrast, a higher rate of TRM is seen following BMT with unmanipulated marrows reflecting the higher complication rate with this procedure. In large registry studies of such patients with a median age of 20-30 years, TRM for good-risk leukemias was 25-30% and for high-risk leukemias was 40-50%. 1, 47 TRM also was dependent on the extent of immunosuppression used in this study. TRM was 38% for patients receiving 30 days of CsA compared to 22% for patients receiving у80 days of CsA. The latter group also included the three fatal graft failures accounting for 4% TRM. By using optimal immunoprophylaxis of GVHD and by taking measures to minimize graft failure as discussed above, TRM in the 15-20% range is a reasonable expectation.
Relapse clearly remains a significant problem with T cell-depleted allografts. Given the improved engraftment and reduction of TRM by graft engineering methodology, we now have an opportunity to reduce the rate of relapse further by means of immune therapy such as donor leukocyte infusions, 48, 49 IL-2 post-BMT to augment NK cell activity [50] [51] [52] or add-back of selected T cell subsets which potentially could have GVL activity. Although survival outcome was not an endpoint of this study because of population heterogeneity it appeared that use of CD34 + cell-augmented elutriated marrow grafts may provide a good approach to potentially curative therapy for older, high-risk patients with MDS, secondary AML or MM. EFS was better or comparable to results of BMT using unmanipulated marrow transplants. [53] [54] [55] Greater numbers of patients will be required to evaluate survival data more accurately, however.
